Lexicon Pharmaceuticals Current Financial Leverage

LXRX
 Stock
  

USD 2.26  0.12  5.61%   

Lexicon Pharmaceuticals' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Lexicon Pharmaceuticals' financial risk is the risk to Lexicon Pharmaceuticals stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Additionally, see the analysis of Lexicon Pharmaceuticals Fundamentals Over Time.
  
Lexicon Pharmaceuticals Total Debt is fairly stable at the moment as compared to the past year. Lexicon Pharmaceuticals reported Total Debt of 13.39 Million in 2021. Debt Non Current is likely to rise to about 290.6 M in 2022, whereas Debt Current is likely to drop slightly above 11.7 M in 2022.

Lexicon Current Financial Burden

Lexicon Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Lexicon Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Lexicon Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Lexicon Pharmaceuticals' stakeholders.

Asset vs Debt

Equity vs Debt

For most companies, including Lexicon Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Lexicon Pharmaceuticals the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
non Currrent Assets Other
-20.4 M
Price Book
2.79
other Assets
136.9 M
liabilities And Stockholders Equity
-1.5 B
total Assets
136.9 M
Operating Margin
(766.50) 
Given the importance of Lexicon Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of Lexicon Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Lexicon Pharmaceuticals to issue bonds at a reasonable cost.

Lexicon Pharmaceuticals Financial Leverage Rating

Lexicon Pharmaceuticals bond ratings play a critical role in determining how much Lexicon Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Lexicon Pharmaceuticals' borrowing costs.
Piotroski F Score
5  Healthy
Beneish M Score

Lexicon Pharmaceuticals Debt to Cash Allocation

As Lexicon Pharmaceuticals follows its natural business cycle, the capital allocation decisions will not magically go away. Lexicon Pharmaceuticals' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 25.42 M in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Lexicon Pharmaceuticals has a current ratio of 3.77, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lexicon Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Lexicon Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lexicon Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lexicon to invest in growth at high rates of return. When we think about Lexicon Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Lexicon Pharmaceuticals Inventories Over Time

Lexicon Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Lexicon Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Lexicon Pharmaceuticals Debt Ratio

    
  9.78   
It appears most of the Lexicon Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lexicon Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lexicon Pharmaceuticals, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a Lexicon Pharmaceuticals debt ratio should be compared their industry average or other competing firms.
Share Download
Share Download

Lexicon Pharmaceuticals Historical Liabilities

While analyzing the current debt level is an essential aspect of forecasting the current year budgeting needs of Lexicon Pharmaceuticals, understanding its historical liability is critical in projecting Lexicon Pharmaceuticals' future earnings, especially during periods of low and high inflation and deflation. Many analysts look at the trend in assets and liabilities and evaluate how Lexicon Pharmaceuticals uses its financing power over time.
In order to fund their growth, businesses such as Lexicon Pharmaceuticals widely use Financial Leverage. For most companies, financial capital is raised by issuing debt securities and by selling common stock. The debt and equity that make up Lexicon Pharmaceuticals' capital structure have many risks and return implications. Leverage is an investment strategy of using borrowed money to increase the potential return of an investment. Please note, the concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Understaning Lexicon Pharmaceuticals Use of Financial Leverage

Lexicon Pharmaceuticals financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Lexicon Pharmaceuticals's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Lexicon Pharmaceuticals assets, the company is considered highly leveraged. Understanding the composition and structure of overall Lexicon Pharmaceuticals debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it.
Last ReportedProjected for 2022
Total Debt13.4 M13.7 M
Debt Current13.4 M11.7 M
Debt Non Current269.3 M290.6 M
Issuance Repayment of Debt Securities-11.7 M-12 M
Long Term Debt to Equity 1.80  1.94 
Debt to Equity Ratio 0.07  0.07 
Please read more on our technical analysis page.

Lexicon Pharmaceuticals Investors Sentiment

The influence of Lexicon Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Lexicon. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Lexicon Pharmaceuticals' public news can be used to forecast risks associated with investment in Lexicon. The trend in average sentiment can be used to explain how an investor holding Lexicon can time the market purely based on public headlines and social activities around Lexicon Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Lexicon Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Lexicon Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Lexicon Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Lexicon Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lexicon Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lexicon Pharmaceuticals' short interest history, or implied volatility extrapolated from Lexicon Pharmaceuticals options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lexicon Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Lexicon Pharmaceuticals Fundamentals Over Time. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for analysis

When running Lexicon Pharmaceuticals price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.63) 
Market Capitalization
426.5 M
Quarterly Revenue Growth YOY
0.7
Return On Assets
(0.33) 
Return On Equity
(0.69) 
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Lexicon Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.